Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.